Blood Plasma Derivatives Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed hematology and immunology journals, plasma industry publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), Plasma Protein Therapeutics Association (PPTA), International Society of Blood Transfusion (ISBT), World Federation of Hemophilia (WFH), National Hemophilia Foundation (NHF), American Society of Hematology (ASH), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), World Health Organization (WHO) Global Health Observatory, European Centre for Disease Prevention and Control (ECDC), Health Canada, Therapeutic Goods Administration (TGA), and national plasma collection reports from key markets including the US Department of Health and Human Services (HHS), China National Health Commission, and EU Eurostat Health Database. These sources were used to collect plasma collection volume statistics, fractionation capacity data, regulatory approval timelines, safety surveillance data, prevalence data for hemophilia and immunodeficiency disorders, and market landscape analysis for albumin, immunoglobulins, coagulation factors, and other plasma derivatives.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Manufacturing & Operations, regulatory affairs heads, plasma sourcing directors, and commercial leaders from plasma fractionation companies and plasma collection centers. The demand-side sources included procurement leads from academic medical centers, hemophilia treatment centers, blood transfusion centers, and specialty clinics, as well as hematologists, immunologists, transfusion medicine specialists, blood bank directors, and hospital pharmacy directors. Market segmentation was validated, plasma collection and fractionation capacity timelines were confirmed, and clinical adoption patterns, pricing dynamics, reimbursement frameworks, and plasma supply chain constraints were gathered through primary research.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

By Region: North America (38%), Europe (28%), Asia-Pacific (25%), Rest of World (9%)

Global market valuation was derived through revenue mapping and plasma volume analysis. The methodology included:

Identification of 35+ key manufacturers and plasma fractionators across North America, Europe, Asia-Pacific, and Latin America

Product mapping across albumin, immunoglobulins (IVIG/SCIG), coagulation factors (Factor VIII, Factor IX, Factor XIII), anti-thrombin III, and fibrinogen categories

Analysis of reported and modeled annual revenues specific to plasma derivative portfolios

Coverage of fractionators representing 80-85% of global market share in 2024

Extrapolation using bottom-up (plasma collection volume × yield rates × ASP by product type and country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations, accounting for plasma supply constraints and fractionation capacity utilization rates